Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion

被引:210
作者
Lu, Yi
Cai, Zhong
Galson, Deborah L.
Xiao, Guozhi
Liu, Yulin
George, Diane E.
Melhem, Mona F.
Yao, Zhi
Zhang, Jian
机构
[1] Univ Pittsburgh, Dept Med, Pittsburgh VA Healthcare Syst, Pittsburgh, PA 15240 USA
[2] Tianjin Med Univ, Dept Immunol, Tianjin, Peoples R China
[3] Allegheny Gen Hosp, Dept Pathol, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA
[5] Univ Pittsburgh, Vet Adm Hlth Care Syst, Pittsburgh, PA USA
关键词
monocyte chemotactic protein-1; prostate cancer; cell proliferation; invasion;
D O I
10.1002/pros.20464
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Monocyte chemotactic protein-1 (MCP-1) plays a key role in the recruitment and activation of monocytes during inflammation. Increased MCP-1 serum levels in patients with various cancers were correlated with advanced stage. Here, we evaluated the role of MCP-1 on prostate cancer (CaP) cell proliferation and invasion. METHODS. Expression of MCP-1 in tissue specimens was analyzed by immunohistochemical staining. MCP-1 production was determined by ELISA in conditioned media collected from primary prostate epithelia (PrEC), LNCaP, C4-2B, PC3 cells, and hFOB. Cell proliferation and invasion were assayed by MTS assay and invasion chambers. RESULTS. All CaP cells, as well as hFOB, produced high amount of MCPA compared to PrEC cells. MCP-1 expression levels were associated with advanced pathologic stage. MCP-1 induced proliferation and invasion of CaP cells and this was abolished partially either by CCR2 antagonist or PI3 Kinase inhibitor. CONCLUSION. MCP-1 acts as a paracrine and autocrine factor for CaP growth and invasion.
引用
收藏
页码:1311 / 1318
页数:8
相关论文
共 37 条
[1]   TUMOR VOLUME AND PROSTATE-SPECIFIC ANTIGEN - IMPLICATIONS FOR EARLY DETECTION AND DEFINING A WINDOW OF CURABILITY [J].
BABAIAN, RJ ;
TRONCOSO, P ;
STEELHAMMER, LC ;
LLORETATRULL, J ;
RAMIREZ, EI .
JOURNAL OF UROLOGY, 1995, 154 (05) :1808-1812
[2]   Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway [J].
Bendre, MS ;
Margulies, AG ;
Walser, B ;
Akel, NS ;
Bhattacharrya, S ;
Skinner, RA ;
Swain, F ;
Ramani, V ;
Mohammad, KS ;
Wessner, LL ;
Martinez, A ;
Guise, TA ;
Chirgwin, JM ;
Gaddy, D ;
Suva, LJ .
CANCER RESEARCH, 2005, 65 (23) :11001-11009
[3]   Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1,-2 and-3 [J].
Broek, IV ;
Asosingh, K ;
Vanderkerken, K ;
Straetmans, N ;
Van Camp, B ;
Van Riet, I .
BRITISH JOURNAL OF CANCER, 2003, 88 (06) :855-862
[4]   Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array [J].
Chetcuti, A ;
Margan, S ;
Mann, S ;
Russell, P ;
Handelsman, D ;
Rogers, J ;
Dong, QH .
PROSTATE, 2001, 47 (02) :132-140
[5]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[6]   Pathological and molecular aspects of prostate cancer [J].
DeMarzo, AM ;
Nelson, WG ;
Isaacs, WB ;
Epstein, JI .
LANCET, 2003, 361 (9361) :955-964
[7]   Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging (Reprinted from J Urol, vol 111, pg 58-64, 1974) [J].
Gleason, DF ;
Mellinger, GT .
JOURNAL OF UROLOGY, 2002, 167 (02) :953-958
[8]   MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B [J].
Gosling, J ;
Slaymaker, S ;
Gu, L ;
Tseng, S ;
Zlot, CH ;
Young, SG ;
Rollins, BJ ;
Charo, IF .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) :773-778
[9]   Cancer statistics, 2001 [J].
Greenlee, RT ;
Hill-Harmon, MB ;
Murray, T ;
Thun, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2001, 51 (01) :15-36
[10]   Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients [J].
Hefler, L ;
Tempfer, C ;
Heinze, G ;
Mayerhofer, K ;
Breitenecker, G ;
Leodolter, S ;
Reinthaller, A ;
Kainz, C .
BRITISH JOURNAL OF CANCER, 1999, 81 (05) :855-859